Vertex Pharmaceuticals reports earnings, beating EPS, revenue estimates

Welcome back to Overtime. Vertex earnings are out. The stocks lower.Angelica Peebles has the numbers. Angelica. Hey, John.Well, Vertex beating on the top and bottom line, but the bigger news here is that they're saying that their next generation pain drug, VX993, failed in a phase 2 trial, and as a result, they are not moving forward with that drug. Remember, pain is becoming an increasingly big area for Vert. Ex.They had a drug approved just earlier this year, Javics, that appears to be getting off to a li ...